Floatz logo

Ibrutinib

Chronic Hepatitis B

The University of Hong KongSmall moleculePhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
89/ 100

Competitive context

13 Active assets in the Chronic Hepatitis B cohort.

Asset / SponsorPhaseRating
Lamivudine
Yonsei University
Phase 4BBB
Entecavir
Beijing Continent Pharmaceutical Co, Ltd.
Phase 4BBB
TENOFOVIR DISOPROXIL FUMARATE
Ningbo No.2 Hospital
Phase 4BBB
Telbivudine
The Fifth People's Hospital of Suzhou
Phase 4BBB
Adefovir Dipivoxil
Asian-Pacific Alliance of Liver Disease, Beijing
Phase 4BB

View all 29 →

Same molecule, other indications

Ibrutinib is also rated in:

lymphoid leukemiaDormant
BBB
Indicative ·
72 / 100
View asset →
Waldenstrom macroglobulinemiaDormant
BB
Indicative ·
70 / 100
View asset →
B-cell chronic lymphocytic leukemiaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →